Eisai's Akynzeo, a combination antiemetic drug, is currently available in the United States and Europe. It is approved for the prevention of delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [1][2].
When can you get Akynzeo?
Akynzeo is available to patients prescribed by their healthcare provider. Its availability is subject to prescription and dispensing through pharmacies [1][2].
What is Akynzeo used for?
Akynzeo is indicated for the acute and delayed prevention of chemotherapy-induced nausea and vomiting (CINV) in adults [1][2]. It is typically administered prior to the start of chemotherapy [3].
How does Akynzeo work?
Akynzeo combines netupitant, a selective NK1 receptor antagonist, with palonosetron, a 5-HT3 receptor antagonist [1][2]. This dual mechanism targets two key pathways involved in chemotherapy-induced nausea and vomiting [3].
How does Akynzeo compare to other antiemetics?
Akynzeo's combination of netupitant and palonosetron offers a broad spectrum of activity against both acute and delayed CINV. Clinical trials have demonstrated its efficacy in preventing nausea and vomiting compared to placebo and other antiemetic regimens [4][5].
What is the patent status of Akynzeo?
The patent protection for Akynzeo influences its market exclusivity. DrugPatentWatch.com provides detailed information on patent expiry dates and related intellectual property for pharmaceuticals like Akynzeo [6].
Who manufactures Akynzeo?
Akynzeo is developed and marketed by Eisai Co., Ltd. [1].
What are the clinical trial results for Akynzeo?
Clinical studies have shown that Akynzeo, when used in combination with a corticosteroid, significantly improves complete response rates for both acute and delayed CINV in patients receiving highly emetogenic chemotherapy [4][5].
Where can I find more information on Akynzeo?
Further details regarding Akynzeo's availability, prescribing information, and clinical data can be found on Eisai's official websites and through healthcare professional resources [1][2]. Information on patent status and expiry can be accessed via DrugPatentWatch.com [6].
Sources:
1. https://www.eisai.com/news/2014/news20141010.html
2. https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692489/
4. https://pubmed.ncbi.nlm.nih.gov/25047790/
5. https://ascopubs.org/doi/abs/10.1200/JCO.2014.57.1418
6. https://drugpatentwatch.com/